Moderna shares surge after it says experimental mRNA cancer treatment passed key test
First publishedAug 19, 15:42 UTC
Last updatedAug 21, 03:10 UTC · 9m ago
1 outlet
Seattle Times1 outlet
PBS NewsHour1 outlet
MarketWatch
3 outlets over time — hover a bar for its window & outletslast updated
Answer
Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors.
Reported by 3 outlets — PBS NewsHour, MarketWatch, Seattle Times. See all sources ↓
Read the full report at PBS NewsHour ↗
Why it matters
3 outlets are covering this world story — one to watch as reporting develops.
In brief
- What's the story?
- Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors.
- How widely is it covered?
- 3 outlets, average source rating 7.0/10.
- When was it last updated?
- 9m ago.
Different angles across outlets
Coverage map
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card3 outlets1CoverageScouting report
Moderna’s personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped
Sources3TypeCoverage
Sources (3)
Avg source rating 7.0/10Processing cluster
A1A2A3B1B2B3